David A Cameron

List of Publications by Year
in descending order

227	35,035	9234	3394
papers	citations	74	183
		h-index	g-index

231	231	231	26442
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer. New England Journal of Medicine, 2005, 353, 1659-1672.	13.9	4,601
2	Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet, The, 2014, 384, 164-172.	6.3	3,224
3	Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer. New England Journal of Medicine, 2006, 355, 2733-2743.	13.9	3,119
4	Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. New England Journal of Medicine, 2016, 375, 1738-1748.	13.9	1,390
5	2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet, The, 2007, 369, 29-36.	6.3	1,361
6	Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17. Journal of the National Cancer Institute, 2005, 97, 1262-1271.	3.0	1,048
7	Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. New England Journal of Medicine, 2022, 387, 9-20.	13.9	854
8	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. New England Journal of Medicine, 2020, 382, 597-609.	13.9	789
9	11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet, The, 2017, 389, 1195-1205.	6.3	770
10	A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Research and Treatment, 2008, 112, 533-543.	1.1	732
11	Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncology, The, 2015, 16, 266-273.	5.1	709
12	Triple-negative breast cancer: disease entity or title of convenience?. Nature Reviews Clinical Oncology, 2010, 7, 683-692.	12.5	708
13	Identification of molecular apocrine breast tumours by microarray analysis. Oncogene, 2005, 24, 4660-4671.	2.6	694
14	Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncology, The, 2011, 12, 236-244.	5.1	575
15	A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nature Medicine, 2009, 15, 68-74.	15.2	566
16	2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet, The, 2013, 382, 1021-1028.	6.3	447
17	Breast-Cancer Adjuvant Therapy with Zoledronic Acid. New England Journal of Medicine, 2011, 365, 1396-1405.	13.9	429
18	Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer. Annals of Surgical Oncology, 2012, 19, 1508-1516.	0.7	401

#	Article	IF	Citations
19	Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncology, The, 2013, 14, 933-942.	5.1	370
20	Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. Journal of Clinical Oncology, 2020, 38, 2610-2619.	0.8	331
21	The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Human Reproduction, 2006, 21, 2583-2592.	0.4	323
22	1st International consensus guidelines for advanced breast cancer (ABC 1). Breast, 2012, 21, 242-252.	0.9	291
23	Phase III Study Comparing Exemestane With Tamoxifen As First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. Journal of Clinical Oncology, 2008, 26, 4883-4890.	0.8	287
24	Lapatinib Plus Capecitabine in Women with HER-2–Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial. Oncologist, 2010, 15, 924-934.	1.9	277
25	Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG) Tj ETQq1 1 0.784314 rgBT /Over	5.1	247
26	Breast cancer in pregnancy: Recommendations of an international consensus meeting. European Journal of Cancer, 2010, 46, 3158-3168.	1.3	238
27	6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet, The, 2019, 393, 2599-2612.	6.3	225
28	Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. New England Journal of Medicine, 2022, 386, 942-950.	13.9	220
29	Phase III Multicenter Clinical Trial of the Sialyl-TN (STn)-Keyhole Limpet Hemocyanin (KLH) Vaccine for Metastatic Breast Cancer. Oncologist, 2011, 16, 1092-1100.	1.9	215
30	Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer. Journal of Clinical Oncology, 2010, 28, 1131-1137.	0.8	214
31	Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Annals of Oncology, 2003, 14, 1391-1398.	0.6	209
32	Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01). Journal of Clinical Oncology, 2014, 32, 2159-2165.	0.8	207
33	Pretreatment Serum Anti-Müllerian Hormone Predicts Long-Term Ovarian Function and Bone Mass after Chemotherapy for Early Breast Cancer. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1336-1343.	1.8	200
34	Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. Lancet Oncology, The, 2020, 21, 1296-1308.	5.1	196
35	Multi-omic machine learning predictor of breast cancer therapy response. Nature, 2022, 601, 623-629.	13.7	187
36	Late Extended Adjuvant Treatment With Letrozole Improves Outcome in Women With Early-Stage Breast Cancer Who Complete 5 Years of Tamoxifen. Journal of Clinical Oncology, 2008, 26, 1948-1955.	0.8	176

#	Article	IF	Citations
37	CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). Lancet Oncology, The, 2013, 14, 244-248.	5.1	172
38	Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Annals of Oncology, 2008, 19, 1090-1096.	0.6	168
39	Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet, The, 2009, 373, 1681-1692.	6.3	168
40	Phase III Randomized Trial of Doxorubicin and Docetaxel Versus Doxorubicin and Cyclophosphamide As Primary Medical Therapy in Women With Breast Cancer: An Anglo-Celtic Cooperative Oncology Group Study. Journal of Clinical Oncology, 2005, 23, 2988-2995.	0.8	166
41	Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others. Journal of the National Cancer Institute, 2016, 108, djw050.	3.0	166
42	HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncology, The, 2011, 12, 1134-1142.	5.1	165
43	HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer. Clinical Cancer Research, 2008, 14, 7861-7870.	3.2	159
44	Adjuvant interferon alpha 2b in high risk melanoma â€" the Scottish study. British Journal of Cancer, 2001, 84, 1146-1149.	2.9	156
45	Letrozole Suppresses Plasma Estradiol and Estrone Sulphate More Completely Than Anastrozole in Postmenopausal Women With Breast Cancer. Journal of Clinical Oncology, 2008, 26, 1671-1676.	0.8	156
46	Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncology, The, 2022, 23, 149-160.	5.1	148
47	Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13â€˜864 women in seven randomised trials. Lancet Oncology, The, 2021, 22, 1139-1150.	5.1	147
48	Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. British Journal of Cancer, 2005, 92, 1869-1876.	2.9	144
49	Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2â€"Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor. Clinical Cancer Research, 2010, 16, 2688-2695.	3.2	137
50	What Are the Current Standards of Care and Recent Developments in the Management of Breast Cancer?. Oncologist, 2006, 11, 1-3.	1.9	129
51	ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. Contemporary Clinical Trials, 2016, 51, 56-64.	0.8	129
52	Efficacy of Letrozole Extended Adjuvant Therapy According to Estrogen Receptor and Progesterone Receptor Status of the Primary Tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. Journal of Clinical Oncology, 2007, 25, 2006-2011.	0.8	126
53	Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncology, The, 2010, 11, 266-274.	5.1	122
54	TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncology, The, 2011, 12, 527-539.	5.1	116

#	Article	IF	Citations
55	Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2015, 16, 656-666.	5.1	114
56	The requirements of a specialist breast centre. Breast, 2020, 51, 65-84.	0.9	111
57	Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. British Journal of Cancer, 2003, 89, 1837-1842.	2.9	108
58	Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer. European Journal of Cancer, 2013, 49, 3404-3411.	1.3	108
59	Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation. European Journal of Cancer, 2017, 70, 146-155.	1.3	108
60	High hospital research participation and improved colorectal cancer survival outcomes: a population-based study. Gut, 2017, 66, 89-96.	6.1	107
61	Mammostrat®as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy. Breast Cancer Research, 2010, 12, R47.	2.2	104
62	Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01–04) for women with stage II/III breast cancer. Breast Cancer Research and Treatment, 2011, 127, 429-438.	1.1	97
63	Reduced MLH1 Expression in Breast Tumors After Primary Chemotherapy Predicts Disease-Free Survival. Journal of Clinical Oncology, 2000, 18, 87-87.	0.8	96
64	Type 1 Receptor Tyrosine Kinase Profiles Identify Patients With Enhanced Benefit From Anthracyclines in the BR9601 Adjuvant Breast Cancer Chemotherapy Trial. Journal of Clinical Oncology, 2008, 26, 5027-5035.	0.8	90
65	Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Research and Treatment, 2006, 99, 295-300.	1.1	89
66	Increase in response rate by prolonged treatment with neoadjuvant letrozole. Breast Cancer Research and Treatment, 2009, 113, 145-151.	1.1	89
67	Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II–III Melanoma Adjuvant Therapy. Journal of the National Cancer Institute, 2018, 110, 87-96.	3.0	89
68	Continuous 5-fluorouracil in the treatment of breast cancer. British Journal of Cancer, 1994, 70, 120-124.	2.9	88
69	Letrozole as Primary Medical Therapy for Locally Advanced and Large Operable Breast Cancer. Breast Cancer Research and Treatment, 2001, 66, 191-199.	1.1	87
70	Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. Cancer Chemotherapy and Pharmacology, 1999, 44, 453-460.	1.1	86
71	Aromatase inhibitors and arthralgia. Journal of Clinical Oncology, 2001, 19, 2767.	0.8	83
72	The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'. Annals of Oncology, 2004, 15, 211-217.	0.6	79

#	ARTICLE	IF	CITATIONS
73	Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. Annals of Oncology, 2013, 24, 355-361.	0.6	78
74	Maximizing clinical benefit with trastuzumab. Seminars in Oncology, 2004, 31, 35-44.	0.8	75
75	Drug Insight: intracellular inhibitors of HER2â€"clinical development of lapatinib in breast cancer. Nature Clinical Practice Oncology, 2008, 5, 512-520.	4.3	75
76	Economic Evaluation of Genomic Testâ€"Directed Chemotherapy for Early-Stage Lymph Nodeâ€"Positive Breast Cancer. Journal of the National Cancer Institute, 2012, 104, 56-66.	3.0	75
77	Ras/Raf-1/MAPK Pathway Mediates Response to Tamoxifen but not Chemotherapy in Breast Cancer Patients. Clinical Cancer Research, 2009, 15, 1487-1495.	3.2	71
78	Primary systemic therapy for operable breast cancer - 10-year survival data after chemotherapy and hormone therapy. British Journal of Cancer, 1997, 76, 1099-1105.	2.9	70
79	Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer. Gynecologic Oncology, 2007, 106, 461-468.	0.6	67
80	Human Epidermal Growth Factor Receptor 2 Status Correlates With Lymph Node Involvement in Patients With Estrogen Receptor (ER) â€"Negative, but With Grade in Those With ER-Positive Early-Stage Breast Cancer Suitable for Cytotoxic Chemotherapy. Journal of Clinical Oncology, 2007, 25, 4423-4430.	0.8	66
81	Conventional Adjuvant Chemotherapy Versus Single-Cycle, Autograft-Supported, High-Dose, Late-Intensification Chemotherapy in High-Risk Breast Cancer Patients: A Randomized Trial. Journal of the National Cancer Institute, 2004, 96, 1076-1083.	3.0	64
82	In situ detection of HER2:HER2 and HER2:HER3 proteinâ€"protein interactions demonstrates prognostic significance in early breast cancer. Breast Cancer Research and Treatment, 2012, 132, 463-470.	1.1	63
83	Bone mineral density loss during adjuvant chemotherapy in pre-menopausal women with early breast cancer: is it dependent on oestrogen deficiency?. Breast Cancer Research and Treatment, 2010, 123, 805-814.	1.1	62
84	Future options with capecitabine (Xeloda) in (neo)adjuvant treatment of breast cancer. Seminars in Oncology, 2004, 31, 45-50.	0.8	61
85	Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncology, The, 2017, 18, 929-945.	5.1	58
86	Phase III Trial of Epirubicin Plus Paclitaxel Compared With Epirubicin Plus Cyclophosphamide As First-Line Chemotherapy for Metastatic Breast Cancer: United Kingdom National Cancer Research Institute Trial AB01. Journal of Clinical Oncology, 2005, 23, 8322-8330.	0.8	57
87	Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Annals of Oncology, 2008, 19, 877-882.	0.6	57
88	The expression of Ki-S1 and BCL-2 and the response to primary tamoxifen therapy in elderly patients with breast cancer. Breast Cancer Research and Treatment, 1997, 44, 123-133.	1.1	56
89	Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling. Molecular Cancer Therapeutics, 2007, 6, 93-100.	1.9	56
90	Predicting Anthracycline Benefit: *TOP2A* and CEP17â€"Not Only but Also. Journal of Clinical Oncology, 2015, 33, 1680-1687.	0.8	55

#	Article	IF	Citations
91	Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy. Journal of Steroid Biochemistry and Molecular Biology, 2001, 79, 103-107.	1.2	54
92	Insulin-like Growth Factor Binding Proteins IGFBP3, IGFBP4, and IGFBP5 Predict Endocrine Responsiveness in Patients with Ovarian Cancer. Clinical Cancer Research, 2007, 13, 1438-1444.	3.2	54
93	OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer. Health Technology Assessment, 2016, 20, 1-202.	1.3	53
94	Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. Breast Cancer Research and Treatment, 2009, 117, 577-589.	1.1	52
95	Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0. Journal of Clinical Oncology, 2021, 39, 2720-2731.	0.8	52
96	Current perspective â€" Trastuzumab. European Journal of Cancer, 2009, 45, 12-18.	1.3	51
97	Adjuvant chemotherapy in older women (ACTION) study â€" what did we learn from the pilot phase?. British Journal of Cancer, 2011, 105, 1260-1266.	2.9	51
98	Lessons from the use of aromatase inhibitors in the neoadjuvant setting.. Endocrine-Related Cancer, 1999, 6, 227-230.	1.6	49
99	Endocrine therapy resistance can be associated with high estrogen receptor Î± (ERÎ±) expression and reduced ERÎ± phosphorylation in breast cancer models. Endocrine-Related Cancer, 2006, 13, 1121-1133.	1.6	49
100	Updated Cost-Effectiveness Analysis of Trastuzumab for Early Breast Cancer. Pharmacoeconomics, 2011, 29, 415-432.	1.7	48
101	Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial. The Lancet Gastroenterology and Hepatology, 2019, 4, 854-862.	3.7	47
102	Tamoxifen induced apoptosis in ZR-75 breast cancer xenografts antedates tumour regression. Breast Cancer Research and Treatment, 1997, 45, 99-107.	1.1	45
103	Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial. Lancet Oncology, The, 2017, 18, 1543-1552.	5.1	45
104	Quality of life and sexual function after high-dose or conventional chemotherapy for high-risk breast cancer. British Journal of Cancer, 2006, 95, 1626-1631.	2.9	44
105	Osteonecrosis of the Jaw and Oral Healthâ€"Related Quality of Life After Adjuvant Zoledronic Acid: An Adjuvant Zoledronic Acid to Reduce Recurrence Trial Subprotocol (BIG01/04). Journal of Clinical Oncology, 2013, 31, 2685-2691.	0.8	41
106	A Comparative Study of Exemestane Versus Anastrozole in Patients with Postmenopausal Breast Cancer with Visceral Metastases. Clinical Breast Cancer, 2009, 9, 39-44.	1.1	40
107	Anti-MÃ¼llerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review. Human Reproduction Update, 2022, 28, 417-434.	5.2	40
108	Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cells. Carcinogenesis, 2006, 27, 729-739.	1.3	39

#	Article	IF	Citations
109	Strengthening clinical cancer research in the United Kingdom. British Journal of Cancer, 2011, 104, 1529-1534.	2.9	39
110	Magnitude of Trastuzumab Benefit in Patients With HER2-Positive, Invasive Lobular Breast Carcinoma: Results From the HERA Trial. Journal of Clinical Oncology, 2013, 31, 1954-1960.	0.8	39
111	Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer. Breast Cancer Research, 2010, 12, R39.	2.2	37
112	Intensive Loading Dose of Trastuzumab Achieves Higher-Than-Steady–State Serum Concentrations and Is Well Tolerated. Journal of Clinical Oncology, 2010, 28, 960-966.	0.8	37
113	Trial design on prophylaxis and treatment of brain metastases: Lessons learned from the EORTC Brain Metastases Strategic Meeting 2012. European Journal of Cancer, 2012, 48, 3439-3447.	1.3	37
114	A highly-sensitive anti-Müllerian hormone assay improves analysis of ovarian function following chemotherapy for early breast cancer. European Journal of Cancer, 2014, 50, 2367-2374.	1.3	37
115	Docetaxel in Combination With Doxorubicin and Cyclophosphamide As Adjuvant Treatment for Early Node-Positive Breast Cancer: A Cost-Effectiveness and Cost-Utility Analysis. Journal of Clinical Oncology, 2008, 26, 925-933.	0.8	36
116	Nottingham Prognostic Index Plus: Validation of a clinical decision making tool in breast cancer in an independent series. Journal of Pathology: Clinical Research, 2016, 2, 32-40.	1.3	36
117	Cancer survivorship: Reproductive health outcomes should be included in standard toxicity assessments. European Journal of Cancer, 2021, 144, 310-316.	1.3	34
118	Health care costs for the treatment of breast cancer recurrent events: estimates from a UK-based patient-level analysis. British Journal of Cancer, 2007, 97, 479-485.	2.9	33
119	Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer. British Journal of Cancer, 2008, 99, 711-715.	2.9	33
120	Factors predictive of locoregional recurrence following neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancer: An analysis of the EORTC 10994/BIG 1-00 study. European Journal of Cancer, 2017, 79, 226-234.	1.3	33
121	Predictive signatures for chemotherapy sensitivity in breast cancer: Are they ready for use in the clinic?. European Journal of Cancer, 2009, 45, 1733-1743.	1.3	32
122	Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial. Journal of the National Cancer Institute, 2018, 110, 871-879.	3.0	32
123	On-treatment biomarkers can improve prediction of response to neoadjuvant chemotherapy in breast cancer. Breast Cancer Research, 2019, 21, 73.	2.2	32
124	Histopathology of breast carcinoma following neoadjuvant systemic therapy: a common association between letrozole therapy and central scarring. Histopathology, 2007, 51, 219-226.	1.6	31
125	Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim Trial. Value in Health, 2017, 20, 1311-1318.	0.1	31
126	Combining clustering and classification ensembles: A novel pipeline to identify breast cancer profiles. Artificial Intelligence in Medicine, 2019, 97, 27-37.	3.8	30

#	ARTICLE	IF	CITATIONS
127	Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population-based study of Scottish cancer registry data. British Journal of Cancer, 2020, 123, 852-859.	2.9	30
128	Proximity ligation assays for isoformâ€specific Akt activation in breast cancer identify activated Akt1 as a driver of progression. Journal of Pathology, 2012, 227, 481-489.	2.1	29
129	Assessment of the Effect of Chemotherapy on Ovarian Function in Women With Breast Cancer. Journal of Clinical Oncology, 2007, 25, 1630-1631.	0.8	28
130	Targeting anthracyclines in early breast cancer: new candidate predictive biomarkers emerge. Oncogene, 2010, 29, 5231-5240.	2.6	28
131	Tamoxifen treatment failure in cancer and the nonlinear dynamics of TGFÎ². Journal of Theoretical Biology, 2004, 229, 101-111.	0.8	27
132	Histological grading of invasive breast carcinoma â€" a simplification of existing methods in a large conservation series with longâ€term followâ€up. Histopathology, 2009, 55, 724-731.	1.6	27
133	Chromosome instability and benefit from adjuvant anthracyclines in breast cancer. British Journal of Cancer, 2012, 107, 71-74.	2.9	27
134	Breast cancer patientsâ€™ experiences on endocrine therapy: monitoring with a checklist for patients on endocrine therapy (C-PET). Breast, 2004, 13, 363-368.	0.9	25
135	Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptorâ€"Positive/Human Epidermal Growth Factor Receptor 2â€"Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03). Journal of Clinical Oncology, 2022, 40, 449-458.	0.8	25
136	Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer. British Journal of Cancer, 1996, 74, 2008-2012.	2.9	24
137	Ibandronate: Its Role in Metastatic Breast Cancer. Oncologist, 2006, 11, 27-33.	1.9	24
138	Trastuzumab-associated cardiac events in the Persephone trial. British Journal of Cancer, 2016, 115, 1462-1470.	2.9	23
139	Safety of Oral Ibandronate in the??Treatment of Bone Metastases from??Breast Cancer. Clinical Drug Investigation, 2006, 26, 43-48.	1.1	21
140	Progressive Loss of Estrogen Receptor Î± Cofactor Recruitment in Endocrine Resistance. Molecular Endocrinology, 2007, 21, 2615-2626.	3.7	21
141	Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab. European Journal of Health Economics, 2012, 13, 589-603.	1.4	21
142	Advancing cancer drug discovery towards more agile development of targeted combination therapies. Future Medicinal Chemistry, 2012, 4, 87-105.	1.1	19
143	Species differences in tumour responses to cancer chemotherapy. Philosophical Transactions of the Royal Society B: Biological Sciences, 2015, 370, 20140233.	1.8	19
144	A prognostic index for operable, node-negative breast cancer. British Journal of Cancer, 2004, 90, 1933-1941.	2.9	18

#	ARTICLE	IF	CITATIONS
145	An Economic Evaluation of Docetaxel and Paclitaxel Regimens in Metastatic Breast Cancer in the UK. Pharmacoeconomics, 2009, 27, 847-859.	1.7	18
146	Impact of Screening and Risk Factors for Local Recurrence and Survival After Conservative Surgery and Radiotherapy for Early Breast Cancer: Results From a Large Series With Long-Term Follow-Up. International Journal of Radiation Oncology Biology Physics, 2012, 83, 829-838.	0.4	18
147	Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2017, 18, 755-769.	5.1	18
148	Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer. British Journal of Cancer, 2008, 99, 1984-1990.	2.9	17
149	The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients. European Journal of Cancer, 2008, 44, 353-365.	1.3	17
150	Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer. Journal of Clinical Oncology, 2016, 34, 936-944.	0.8	17
151	Infusional 5-fluorouracil in breast cancer. Cancer Treatment Reviews, 1994, 20, 357-364.	3.4	16
152	The p160 ER co-regulators predict outcome in ER negative breast cancer. Breast Cancer Research and Treatment, 2012, 131, 463-472.	1.1	16
153	Overall survival in MERiDiAN, a double-blind placebo-controlled randomised phase III trial evaluating first-line bevacizumab plus paclitaxel for HER2-negative metastatic breast cancer. European Journal of Cancer, 2018, 90, 153-155.	1.3	15
154	The challenges of making informed decisions about treatment and trial participation following a cancer diagnosis: a qualitative study involving adolescents and young adults with cancer and their caregivers. BMC Health Services Research, 2020, 20, 25.	0.9	15
155	Proven efficacy of zoledronic acid in the treatment of bone metastases in patients with breast cancer and other malignancies. Breast, 2003, 12, S22-S29.	0.9	14
156	Health economics in drug development: Efficient research to inform healthcare funding decisions. European Journal of Cancer, 2010, 46, 2674-2680.	1.3	14
157	Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials. British Journal of Cancer, 2012, 107, 1257-1267.	2.9	14
158	FKBPL: a marker of good prognosis in breast cancer. Oncotarget, 2015, 6, 12209-12223.	0.8	13
159	Locally advanced breast cancer: the outcome of primary polychemotherapy based on infusional 5 fluorouracil. Breast, 1999, 8, 110-115.	0.9	12
160	Identification of long-term survivors in primary breast cancer by dynamic modelling of tumour response. British Journal of Cancer, 2000, 83, 98-103.	2.9	12
161	Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial. European Journal of Cancer, 2022, 166, 219-228.	1.3	12
162	Patient management issues in metastatic bone disease. Seminars in Oncology, 2004, 31, 79-82.	0.8	11

#	Article	IF	Citations
163	Opportunities for PET to deliver clinical benefit in cancer: breast cancer as a paradigm. Cancer Imaging, 2010, 10, 144-152.	1.2	11
164	Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes. British Journal of Cancer, 2019, 120, 913-921.	2.9	11
165	Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT. Health Technology Assessment, 2020, 24, 1-190.	1.3	11
166	Lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer. Clinical Advances in Hematology and Oncology, 2007, 5, 456-8.	0.3	11
167	Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Primary Breast Cancer. Journal of Clinical Oncology, 2022, 40, 3699-3708.	0.8	11
168	Mathematical modelling of tumour response in primary breast cancer. British Journal of Cancer, 1996, 73, 1409-1416.	2.9	10
169	Cell killing and resistance in pre-operative breast cancer chemotherapy. BMC Cancer, 2008, 8, 201.	1.1	10
170	Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: an Anglo-Celtic Cooperative Oncology Group Study. Breast Cancer Research and Treatment, 2010, 122, 787-794.	1.1	10
171	Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancer. Breast Cancer Research and Treatment, 2013, 138, 773-781.	1.1	9
172	High-dose chemotherapy supported by peripheral blood progenitor cells in poor prognosis metastatic breast cancer--phase I/II study. British Journal of Cancer, 1996, 74, 2013-2017.	2.9	7
173	The Royal College of Physicians Simms Lecture, 6 December 2011: Clinical research networks and the benefits of intensive healthcare systems. Clinical Medicine, 2012, 12, 446-452.	0.8	7
174	Pertuzumab for the treatment of metastatic breast cancer. Expert Review of Anticancer Therapy, 2013, 13, 907-918.	1.1	7
175	Breast cancer chemoprevention: little progress in practice?. Lancet, The, 2014, 383, 1018-1020.	6.3	7
176	Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience. Breast Cancer Research and Treatment, 2016, 155, 127-132.	1.1	7
177	Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results. Clinical Cancer Research, 2022, 28, 1323-1334.	3.2	7
178	Intraoperative radiotherapy for early breast cancer. Lancet, The, 2010, 376, 1142.	6.3	6
179	Adjuvant trastuzumab duration trials in HER2 positive breast cancer – what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results. BMC Cancer, 2018, 18, 391.	1.1	6
180	Block sequential adriamycin CMF – optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?. British Journal of Cancer, 2002, 87, 1365-1369.	2.9	5

#	Article	IF	Citations
181	Lapatinib for inflammatory breast cancer. Lancet Oncology, The, 2009, 10, 538-539.	5.1	5
182	Reproductive hormone analyses and effects of adjuvant zoledronic acid in early breast cancer â€" An AZURE (BIG 01/04) sub-study. Journal of Bone Oncology, 2017, 9, 48-54.	1.0	5
183	Breast cancer gene expression datasets do not reflect the disease at the population level. Npj Breast Cancer, 2020, 6, 39.	2.3	5
184	Central nervous system disease in phase III studies for advanced HER2 positive breast cancer: A review. Breast, 2022, 63, 85-100.	0.9	5
185	Bevacizumab: the first anti-angiogenic agent approved for the treatment of metastatic breast cancer. European Journal of Cancer, Supplement, 2008, 6, 1-6.	2.2	4
186	The EORTC Breast Cancer Group: major achievements of 50 years of research and future directions. European Journal of Cancer, Supplement, 2012, 10, 27-33.	2.2	4
187	Removing the primary tumour in metastatic breast cancer. Lancet Oncology, The, 2015, 16, 1284-1285.	5.1	4
188	England's 30-day chemotherapy mortality: a measure of quality of care?. Lancet Oncology, The, 2016, 17, 1172-1173.	5.1	4
189	Postcode prescribing is alive and well in Scotland. BMJ: British Medical Journal, 2002, 325, 101a-101.	2.4	4
190	Abstract PD10-05: Activity of atezolizumab (atezo) plus paclitaxel (pac) in metastatic triple-negative breast cancer (mTNBC) according to Burstein molecular subtype: Analysis of the IMpassion131 trial. Cancer Research, 2022, 82, PD10-05-PD10-05.	0.4	4
191	Code of practice needed for samples donated by trial participants. Lancet Oncology, The, 2022, 23, e89-e90.	5.1	4
192	A pilot study of infusional CMF (CMF-inf): Active and well tolerated in breast cancer. Annals of Oncology, 1996, 7, 409-411.	0.6	3
193	Extended follow-up of breast cancer patients in clinic wastes time for both patients and doctors: the case against. Breast Cancer Research, 2008, 10, S8.	2.2	3
194	Expression of activated type I receptor tyrosine kinases in early breast cancer. Breast Cancer Research and Treatment, 2012, 134, 701-708.	1.1	3
195	Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?. Breast Cancer Research, 2013, 15, R31.	2.2	3
196	Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study. Breast Cancer Research and Treatment, 2017, 163, 507-515.	1.1	3
197	Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: Investigating innate immunity as a tumour suppressor inÂbreast cancer. European Journal of Cancer, 2017, 72, 95-102.	1.3	3
198	Patterns of genomic change in residual disease after neoadjuvant chemotherapy for estrogen receptor-positive and HER2-negative breast cancer. British Journal of Cancer, 2021, 125, 1356-1364.	2.9	3

#	Article	IF	Citations
199	Modelling the Effects of Paclitaxel and Cisplatin on Breast and Ovarian Cancer. Journal of Theoretical Medicine, 2000, 3, 11-23.	0.5	2
200	Foundation clinical trials. Breast Cancer Research, 2009, 11, S23.	2.2	2
201	Developing an international network for breast cancer research: the BIG experience. Clinical Investigation, 2011, 1, 623-628.	0.0	2
202	Characterizing and quantifying the effects of breast cancer therapy using mathematical modeling. Breast Cancer Research and Treatment, 2016, 155, 303-311.	1.1	2
203	Impact of steroid premedication on atezolizumab (atezo)-induced immune cell activation: A comparative analysis of IMpassion130 and IMpassion131 peripheral blood mononuclear cells (PBMCs).. Journal of Clinical Oncology, 2022, 40, 1083-1083.	0.8	2
204	Brachial plexopathy affecting the development of Beau's lines unilaterally. Lancet Oncology, The, 2001, 2, 342.	5.1	1
205	Breast cancer vaccines: current research and future prospects. Expert Review of Vaccines, 2002, 1, 29-34.	2.0	1
206	Role of bisphosphonate therapy in breast cancer and other advanced malignancies. Breast, 2003, 12, S20-S21.	0.9	1
207	Chemotherapy, Trastuzumab, and Pathological Complete Response: When Shall We Three Meet Again?. Journal of Clinical Oncology, 2011, 29, 3344-3345.	0.8	1
208	Do patients whose tumor achieved a pathological response relapse at specific sites? A substudy of the EORTC 10994/BIG-1-00 trial. Breast Cancer Research and Treatment, 2018, 169, 497-505.	1.1	1
209	Strategies for improving access to clinical trials by teenagers and young adults with cancer: A qualitative study of health professionals' views. European Journal of Cancer Care, 2021, 30, e13408.	0.7	1
210	Expert Discussion: Highlights from the San Antonio Breast Cancer Symposium, San Antonio, December 8–11, 2020. Breast Care, 2021, 16, 89-93.	0.8	1
211	Treatment of Screen-Detected Breast Cancer: Can We Avoid or Minimize Overtreatment?. , 2016, , 375-401.		1
212	Breast Cancer Therapy Annual – today's drug treatment of cancer?. Breast Cancer Research, 2003, 6, 1.	2.2	0
213	Should all adjuvant breast cancer patients receive a bisphosphonate?. Breast Cancer Research, 2003, 5, 296-9.	2.2	0
214	Paclitaxel in Early Breast Cancer. Drugs, 2004, 64, 1848-1849.	4.9	0
215	Time for a change in breast cancer therapy?. British Journal of Hospital Medicine, 2004, 65, 724-729.	0.3	0
216	Promises borne out in clinical studies. European Journal of Cancer, Supplement, 2008, 6, 15-24.	2.2	0

#	Article	IF	Citations
217	Lapatinib in the management of breast cancer. Therapy: Open Access in Clinical Medicine, 2009, 6, 553-568.	0.2	0
218	Authors' Reply. Journal of Pathology, 2013, 229, e2-3.	2.1	0
219	Concerns about cardiotoxicity in the HERA trial â€" Authors' reply. Lancet, The, 2017, 390, 2767-2768.	6.3	0
220	Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial. Anticancer Research, 2019, 39, 797-802.	0.5	0
221	Protective strategies to prevent trastuzumab-induced cardiotoxicity â€" Authors' reply. Lancet, The, 2020, 395, 492-493.	6.3	0
222	Abstract OT-14-01: Adaption of the EORTC quality of life breast cancer module for male breast cancer - phase I. , 2021, , .		0
223	Adjuvant Systemic Treatment for Breast Cancer: An Overview. , 2016, , 311-321.		0
224	Collateral-resistance to estrogen and HER-activated growth is associated with modified AKT, ERÎ±, and cell-cycle signaling in a breast cancer model. Exploration of Targeted Anti-tumor Therapy, 2022, 3, 97-116.	0.5	0
225	Abstract PD9-08: Prognostic value of EndoPredict test in patients screened for UNIRAD, a UCBG randomized, double blind, phase III international trial evaluating the addition of everolimus (EVE) to adjuvant hormone therapy (HT) in women with high risk HR+, HER2- early breast cancer (eBC). Cancer Research, 2022, 82, PD9-08-PD9-08.	0.4	0
226	Scottish COVID CAncer iMmunity Prevalence (SCCAMP): A longitudinal study of patients with cancer receiving active anti-cancer treatment during the COVID-19 pandemic.. Journal of Clinical Oncology, 2022, 40, e18733-e18733.	0.8	0
227	Impact of anti-HER2 therapy alone and in association with weekly paclitaxel on the ovarian reserve of young women with HER2-positive early breast cancer: Biomarker analysis of the NeoALTTO trial.. Journal of Clinical Oncology, 2022, 40, 12084-12084.	0.8	0